Cancer drug developer Ellipses Pharma explores London listing via Wolfram Resources reverse takeover
Reuters (via Global Banking & Finance Review) · · AI-summarised by FinFlash
British oncology drug developer Ellipses Pharma, founded in 2017, is weighing a London stock market listing through a reverse takeover by special purpose acquisition company Wolfram Resources. Terms have not yet been agreed. The company aims to complete the deal by early 2027 and expects to raise fresh equity alongside it. Founder and chair Chris Evans said the route would open access to public market investors. Its pipeline includes trials in non-small cell lung cancer and breast cancer.
So What?
A rare new biotech listing would be a modest boost for London's struggling IPO market, which has lost companies to US exchanges seeking higher valuations.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.